New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis
The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current resea...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/16/2/239 |
| _version_ | 1797297190827196416 |
|---|---|
| author | Elena Carmona-Rocha Lluís Rusiñol Lluís Puig |
| author_facet | Elena Carmona-Rocha Lluís Rusiñol Lluís Puig |
| author_sort | Elena Carmona-Rocha |
| collection | DOAJ |
| description | The introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on the development of oral therapies with improved efficacy and safety compared with available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate to severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways such as AhR, PDE-4, and Jak-STAT. Tapinarof (an AhR modulator) and roflumilast (a PDE-4 inhibitor) have exhibited favorable efficacy and safety outcomes and have been approved by the FDA for the topical treatment of plaque psoriasis. This revision focuses on the most recent oral and topical therapies available for psoriasis, especially those that are currently under evaluation and development for the treatment of psoriasis. |
| first_indexed | 2024-03-07T22:17:46Z |
| format | Article |
| id | doaj.art-44e4c44a767346fe95a014887f67db90 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-07T22:17:46Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-44e4c44a767346fe95a014887f67db902024-02-23T15:31:11ZengMDPI AGPharmaceutics1999-49232024-02-0116223910.3390/pharmaceutics16020239New and Emerging Oral/Topical Small-Molecule Treatments for PsoriasisElena Carmona-Rocha0Lluís Rusiñol1Lluís Puig2Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, SpainDepartment of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, SpainDepartment of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, SpainThe introduction of biologic therapies has led to dramatic improvements in the management of moderate-to-severe psoriasis. Even though the efficacy and safety of the newer biologic agents are difficult to match, oral administration is considered an important advantage by many patients. Current research is focused on the development of oral therapies with improved efficacy and safety compared with available alternatives, as exemplified by deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for the treatment of moderate to severe psoriasis in adults. Recent advances in our knowledge of psoriasis pathogenesis have also led to the development of targeted topical molecules, mostly focused on intracellular signaling pathways such as AhR, PDE-4, and Jak-STAT. Tapinarof (an AhR modulator) and roflumilast (a PDE-4 inhibitor) have exhibited favorable efficacy and safety outcomes and have been approved by the FDA for the topical treatment of plaque psoriasis. This revision focuses on the most recent oral and topical therapies available for psoriasis, especially those that are currently under evaluation and development for the treatment of psoriasis.https://www.mdpi.com/1999-4923/16/2/239psoriasisoral therapiestopical therapiesbiologicsJak inhibitorsPDE4 inhibitors |
| spellingShingle | Elena Carmona-Rocha Lluís Rusiñol Lluís Puig New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis Pharmaceutics psoriasis oral therapies topical therapies biologics Jak inhibitors PDE4 inhibitors |
| title | New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis |
| title_full | New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis |
| title_fullStr | New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis |
| title_full_unstemmed | New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis |
| title_short | New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis |
| title_sort | new and emerging oral topical small molecule treatments for psoriasis |
| topic | psoriasis oral therapies topical therapies biologics Jak inhibitors PDE4 inhibitors |
| url | https://www.mdpi.com/1999-4923/16/2/239 |
| work_keys_str_mv | AT elenacarmonarocha newandemergingoraltopicalsmallmoleculetreatmentsforpsoriasis AT lluisrusinol newandemergingoraltopicalsmallmoleculetreatmentsforpsoriasis AT lluispuig newandemergingoraltopicalsmallmoleculetreatmentsforpsoriasis |